臨床泌尿器科69巻5号

2015年04月発行

特集 前立腺癌の内分泌療法—気になる最新の動向

放射線外照射に併用する内分泌療法の現状と課題

著者： 三塚浩二¹ 川崎芳英¹ 荒井陽一¹ 神宮啓一²

所属機関： ¹東北大学大学院医学系研究科泌尿器科学分野 ²東北大学大学院医学系研究科放射線腫瘍学分野

ページ範囲：P.360 - P.366

文献概要

要旨　放射線外照射にホルモン療法を併用することにより，抗腫瘍効果が増強し治療成績が向上することがこれまでのいくつかの臨床試験により示されている。しかしながらその対象や期間についてはまだ検討が必要とされている。特にホルモン療法は短期間の使用でもテストステロン抑制に伴うさまざまな有害事象を招く可能性があり，漫然と使用し続けるべきではない。リスク分類や過去の報告を参考にしながら，ホルモン療法に伴う負の側面も考慮し，個々の症例で適切な併用期間の設定が必要である。

参考文献

1）Bolla M, Collette L, Blank L, et al：Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer（an EORTC study）：a phase Ⅲ randomised trial. Lancet 360：103-106, 2002

2）Jones CU, Hunt D, McGowan DG, et al：Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365：107-118, 2011

3）並木幹夫：前立腺癌に対する放射線療法とホルモン療法の相性．JASTRO NEWSLETTER 109：25-26，2013

4）Gay HA, Michalski JM, Hamstra DA, et al：Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life：results of a multicenter prospective study. Urology 82：1363-1368, 2013

5）Ziehr DR, Chen MH, Zhang D, et al：Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 〔Epub ahead of print〕

6）Nanda A, Chen MH, Braccioforte MH, et al：Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302：866-873, 2009

7）Keating NL, O'Malley AJ, Freedland SJ, et al：Diabetes and cardiovascular disease during androgen deprivation therapy：observational study of veterans with prostate cancer. Journal of the National Cancer Institute 102：39-46, 2010

8）Higano CS：Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer：what do we really know? Nature clinical practice Urology 5：24-34, 2008

9）Shahinian VB, Kuo YF, Freeman JL, et al：Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352：154-164, 2005

10）Bliuc D, Nguyen ND, Milch VE, et al：Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301：513-521, 2009

11）Center JR, Nguyen TV, Schneider D, et al：Mortality after all major types of osteoporotic fracture in men and women：an observational study. Lancet 353：878-882, 1999

12）Wang W, Yuasa T, Tsuchiya N, et al：Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocrine-related cancer 15：943-952, 2008

13）Yuasa T, Maita S, Tsuchiya N, et al：Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75：1131-1137, 2010

14）Morote J, Morin JP, Orsola A, et al：Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69：500-504, 2007

15）Pisansky TM, Hunt D, Gomella LG, et al：Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer：Radiation Therapy Oncology Group Randomized Clinical Trial 9910. J Clin Oncol 33：332-339, 2014

16）Pilepich MV, Winter K, Lawton CA, et al：Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase Ⅲ RTOG 85-31. Int J Radiat Oncol Biol Phys 61：1285-1290, 2005

17）Bolla M, Van Tienhoven G, Warde P, et al：External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk：10-year results of an EORTC randomised study. The Lancet Oncol 11：1066-1073, 2010

18）Horwitz EM, Bae K, Hanks GE, et al：Ten-year follow-up of radiation therapy oncology group protocol 92-02：a phase Ⅲ trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26：2497-2504, 2008

19）Bolla M, de Reijke TM, Van Tienhoven G, et al：Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360：2516-2527, 2009

20）Keating NL, O'Malley AJ and Smith MR：Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24：4448-4456, 2006

21）Efstathiou JA, Bae K, Shipley WU, et al：Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer：RTOG 85-31. J Clin Oncol 27：92-99, 2009

22）EAU guidelines 2014：prostate cancer. http://www.uroweb.org/guidelines/online-guidelines/

23）Takeda K, Takai Y, Narazaki K, et al：Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan. Radiat Oncol 7：105, 2012

24）Konaka H, Egawa S, Saito S, et al：Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer（TRIP）：study protocol for a phase Ⅲ, multicenter, randomized, controlled trial. BMC cancer 12：110, 2012

25）Miki J and Egawa S：The role of lymph node dissection in the management of prostate cancer. Int J Clin Oncol 16：195-202, 2011

26）Lawton CA, DeSilvio M, Roach M 3rd, et al：An update of the phase Ⅲ trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression：updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69：646-655, 2007

27）日本泌尿器科学会（編）：前立腺癌診療ガイドライン 2012年版．金原出版，東京，2012

28）Roach M 3rd, Hanks G, Thames H Jr, et al：Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer：recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65：965-974, 2006